XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

NEXT STORY
Itamar Medical Appoints Jennifer Cook, MD, FAHA, FACC, as Global Medical Director
PREV STORY
BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Announces Date of Fourth Quarter and Full Year 2015 Financial Results Conference Call

ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage ...

author_avatar
NASDAQ Market News

Calithera Biosciences to Present at the 15th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 08, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), ...

author_avatar
NASDAQ Market News

Tyme Technologies Inc. (Nasdaq: TYME) to Ring The Nasdaq Stock Market Opening Bell

NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical ...

author_avatar
NASDAQ Market News